Three insulin analogues: rapid-acting, pre-mixed and long-acting.
Our insulin analogues.
Insulin aspart
Approved; marketed since October 2023
Insulin aspart mix
Approved September 2025
Insulin glargine
Phase III completed; approved by SEC
Product information on these pages is intended for healthcare professionals.
Insulin aspart
- Class
- Rapid-acting insulin analogue.
- Reference medicine
- Innovator’s insulin aspart.
- Presentations
- Cartridges, vials and prefilled disposable pens.
- Status
- Approved in India; marketed since October 2023 by USV Private Limited as InsuQuick™. European filing planned for 2027.
Insulin aspart mix
- Class
- Pre-mixed insulin analogue (30% soluble insulin aspart, 70% insulin aspart protamine).
- Reference medicine
- Innovator’s insulin aspart mix 30.
- Status
- Approved in India in September 2025. Launch in India planned.
Insulin glargine
- Class
- Long-acting basal insulin analogue.
- Reference medicine
- Innovator’s insulin glargine.
- Status
- Phase III completed; approved by the Subject Expert Committee (SEC).
Beyond our lead products.
These products span prandial, biphasic, and basal insulin segments, enabling portfolio coverage across multiple treatment regimens in diabetes care. Beyond the lead products, BioGenomics has developed a broader insulin analogue pipeline, leveraging a common platform technology and accumulated process knowledge.
Insulin aspart
Rapid-acting insulin analogue
Reference: innovator’s insulin aspart
Strong physician familiarity; limited biosimilar competition in several markets.
Insulin aspart mix
Pre-mixed insulin analogue
Reference: innovator’s insulin aspart mix 30
Strong physician familiarity; limited biosimilar competition in several markets.
Insulin glargine
Basal insulin
Reference: innovator’s insulin glargine
Established basal insulin with strong physician adoption.
Faster-acting insulin aspart
Ultra-fast insulin analogue
Ultra-rapid insulin segment with lean competition and a straightforward development pathway.
Insulin icodec
Ultra-long insulin analogue
Next-generation once-weekly basal insulin.
Insulin icodec + GLP-1 analogue
Ultra-long insulin analogue + GLP-1 analogue
Next-generation once-weekly basal insulin combined with semaglutide.
Insulin glargine 300 U/mL
Basal insulin (high concentration)
Growing next-generation basal insulin segment with limited biosimilar competition.
Insulin degludec + insulin aspart
Ultra-long insulin analogue + rapid-acting
Long-acting + fast-acting combination.
- Insulin pump
- GLP-1 analogues
- Diabetic foot ulcer cream
We have also developed over 15 biotech non-therapeutic enzymes. Our recombinant enzymes, such as recombinant trypsin, carboxypeptidase B (CPB) and enterokinase, are manufactured at our plant in Puducherry and sold commercially to global customers. They also support our core business, including in-house analytical characterisation, quality-control testing and process-development services. More on our enzymes